161 related articles for article (PubMed ID: 20052748)
1. Phase1/-2 study of Pomalidomide in myelofibrosis.
Mesa RA; Pardanani AD; Hussein K; Wu W; Schwager S; Litzow MR; Hogan WJ; Tefferi A
Am J Hematol; 2010 Feb; 85(2):129-30. PubMed ID: 20052748
[No Abstract] [Full Text] [Related]
2. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
[TBL] [Abstract][Full Text] [Related]
3. Low-dose thalidomide in myelofibrosis.
Weinkove R; Reilly JT; McMullin MF; Curtin NJ; Radia D; Harrison CN
Haematologica; 2008 Jul; 93(7):1100-1. PubMed ID: 18508796
[No Abstract] [Full Text] [Related]
4. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
[TBL] [Abstract][Full Text] [Related]
5. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
Pardanani A; Begna K; Finke C; Lasho T; Tefferi A
Am J Hematol; 2011 Apr; 86(4):343-5. PubMed ID: 21442636
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
[TBL] [Abstract][Full Text] [Related]
9. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Quintas-Cardama A; Jabbour E; Konopleva M; O'Brien S; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2013 Nov; 37(11):1440-4. PubMed ID: 23890523
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of pomalidomide therapy in myelofibrosis.
Begna KH; Pardanani A; Mesa R; Litzow MR; Hogan WJ; Hanson CA; Tefferi A
Am J Hematol; 2012 Jan; 87(1):66-8. PubMed ID: 22081489
[TBL] [Abstract][Full Text] [Related]
12. Does anything work for anaemia in myelofibrosis?
Birgegård G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):175-85. PubMed ID: 25189728
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic myelofibrosis associated with dermatomyositis.
Muslimani A; Ahluwalia MS; Palaparty P; Daw HA
Am J Hematol; 2006 Jul; 81(7):559-60. PubMed ID: 16755562
[No Abstract] [Full Text] [Related]
14. Responses to pomalidomide and placebo in myelofibrosis-related anaemia.
Ross DM
Leukemia; 2017 Mar; 31(3):532-533. PubMed ID: 27932792
[No Abstract] [Full Text] [Related]
15. Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib.
Andrei M; Sindhu H; Wang JC
Leuk Lymphoma; 2015 Feb; 56(2):524-6. PubMed ID: 24893800
[No Abstract] [Full Text] [Related]
16. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Schlenk RF; Stegelmann F; Reiter A; Jost E; Gattermann N; Hebart H; Waller C; Hochhaus A; Platzbecker U; Schafhausen P; Blau IW; Verbeek W; Heidel FH; Werner M; Kreipe H; Teleanu V; Benner A; Döhner H; Grießhammer M; Döhner K
Leukemia; 2017 Apr; 31(4):889-895. PubMed ID: 27774990
[TBL] [Abstract][Full Text] [Related]
17. [Successful treatment of splenomegaly and anemia by VP therapy in idiopathic myelofibrosis complicated with acromegaly: a case report].
Imai Y; Akiyama N; Hanazono Y; Inamori K; Mitani K; Hirai H; Nagai R; Yazaki Y
Rinsho Ketsueki; 1995 Oct; 36(10):1233-6. PubMed ID: 8531337
[TBL] [Abstract][Full Text] [Related]
18. Treatment considerations for primary myelofibrosis.
Biemond BJ
Neth J Med; 2010 Aug; 68(1):291-2. PubMed ID: 20739724
[No Abstract] [Full Text] [Related]
19. Long-term results of prednisone treatment for the anemia of myelofibrosis.
Hernández-Boluda JC; Martínez-Trillos A; García-Gutiérrez V; Ferrer-Marín F; Xicoy B; Alvarez-Larrán A; Kerguelen A; Barba P; Gómez M; Herrera JC; Correa JG; Cervantes F
Leuk Lymphoma; 2016; 57(1):120-4. PubMed ID: 25944376
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclosporin-A on anemia in idiopathic myelofibrosis.
Falcone A; Musto P; Carotenuto M
Haematologica; 1998 Jul; 83(7):665-6. PubMed ID: 9718875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
